This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
allergic rhinitis | 311 |
depressive symptoms | 271 |
mental health | 269 |
specific ige | 217 |
skin prick | 135 |
common cold | 112 |
respiratory symptoms | 112 |
depression symptoms | 110 |
anxiety symptoms | 108 |
food allergy | 104 |
stress symptoms | 104 |
psychological distress | 101 |
case report | 99 |
respiratory tract | 98 |
grass pollen | 97 |
novel coronavirus | 95 |
peritraumatic stress | 92 |
health care | 92 |
sore throat | 91 |
general population | 90 |
nasal spray | 88 |
control group | 86 |
mean age | 85 |
years old | 84 |
asthma symptoms | 84 |
statistically significant | 83 |
cd cd | 79 |
atopic dermatitis | 79 |
risk factors | 79 |
coronavirus disease | 76 |
gi symptoms | 76 |
prick tests | 74 |
dust mite | 74 |
ptsd symptoms | 73 |
prick test | 72 |
healthcare workers | 71 |
significantly higher | 71 |
digestive symptoms | 70 |
house dust | 70 |
total ige | 68 |
primary care | 65 |
mg ml | 65 |
mg dl | 63 |
physical symptoms | 63 |
upper respiratory | 63 |
abdominal pain | 61 |
pg ml | 60 |
medical staff | 59 |
psychological impact | 59 |
prior trauma | 58 |
nasal congestion | 57 |
significant difference | 55 |
total score | 55 |
united states | 54 |
high levels | 53 |
allergic reactions | 53 |
may also | 52 |
skin testing | 52 |
doc id | 51 |
cord uid | 51 |
influenza virus | 51 |
trauma exposure | 50 |
skin tests | 50 |
allergic patients | 50 |
adverse events | 50 |
acute respiratory | 50 |
least one | 50 |
year old | 49 |
skin test | 49 |
present study | 48 |
posttraumatic stress | 48 |
informed consent | 48 |
iu ml | 48 |
seasonal allergic | 47 |
dust mites | 47 |
logistic regression | 47 |
allergic diseases | 47 |
systematic review | 46 |
public health | 45 |
mg kg | 45 |
asthmatic patients | 45 |
asthma control | 45 |
lung function | 44 |
social support | 43 |
gastrointestinal symptoms | 43 |
ige levels | 43 |
health status | 43 |
symptom onset | 42 |
risk factor | 42 |
old male | 42 |
symptoms among | 42 |
nasal symptoms | 41 |
emergency department | 41 |
tract infections | 41 |
specific igg | 41 |
viral infections | 40 |
peanut allergy | 40 |
respiratory infections | 40 |
peripheral blood | 39 |
intergenerational contact | 39 |
world health | 39 |
significant differences | 38 |
respiratory syndrome | 38 |
clinical characteristics | 38 |
young adults | 37 |
side effects | 37 |
ng ml | 37 |
previous studies | 37 |
bronchial asthma | 37 |
copyright holder | 37 |
increased risk | 37 |
somatic symptoms | 37 |
symptom score | 37 |
psychiatric patients | 37 |
traumatic events | 36 |
author funder | 36 |
version posted | 36 |
health organization | 36 |
family history | 36 |
food allergens | 36 |
building syndrome | 36 |
granted medrxiv | 36 |
pulmonary function | 36 |
risk behaviors | 36 |
data collection | 35 |
sectional study | 35 |
related stressors | 35 |
sbs symptoms | 35 |
old female | 35 |
sick building | 35 |
physical examination | 35 |
total symptom | 35 |
study period | 34 |
specific immunotherapy | 34 |
allergic asthma | 34 |
persistent asthma | 34 |
allergic reaction | 34 |
health problems | 34 |
factors associated | 34 |
severe asthma | 34 |
lower respiratory | 33 |
one year | 33 |
symptom scores | 33 |
confirmed cases | 32 |
migraine symptoms | 32 |
asthma severity | 32 |
air quality | 32 |
current study | 32 |
immune system | 32 |
two groups | 32 |
pollen season | 31 |
anxiety disorder | 31 |
positive skin | 31 |
higher levels | 31 |
generalized anxiety | 31 |
airway inflammation | 31 |
made available | 31 |
symptoms related | 31 |
social media | 31 |
symptoms may | 30 |
nausea vomiting | 30 |
food allergies | 30 |
epithelial cells | 30 |
mental disorders | 30 |
serum ige | 30 |
median age | 29 |
clinically significant | 29 |
related symptoms | 29 |
hospitalized patients | 29 |
well tolerated | 29 |
runny nose | 29 |
stress disorder | 29 |
clinical features | 29 |
patients treated | 28 |
healthy controls | 28 |
old woman | 28 |
mast cell | 28 |
traumatic stress | 28 |
respiratory viruses | 28 |
symptom severity | 28 |
severe acute | 28 |
ige binding | 27 |
immune response | 27 |
indoor air | 27 |
international license | 27 |
perceived stress | 27 |
chronic urticaria | 27 |
college students | 26 |
igg levels | 26 |
high risk | 26 |
medical history | 26 |
office buildings | 26 |
viral infection | 26 |
allergic symptoms | 26 |
performed using | 26 |
clinical practice | 26 |
higher risk | 26 |
chest pain | 26 |
mild symptoms | 25 |
respiratory diseases | 25 |
likely path | 25 |
stress group | 25 |
low levels | 25 |
virus infection | 25 |
lay people | 25 |
average age | 25 |
reported symptoms | 25 |
posttraumatic growth | 25 |
hypersensitivity reactions | 25 |
carrageenan nasal | 25 |
cells mm | 25 |
nf swab | 25 |
hearing loss | 25 |
ige level | 25 |
commonly used | 25 |
measured using | 25 |
care workers | 24 |
eosinophil count | 24 |
chain reaction | 24 |
egg white | 24 |
severe depressive | 24 |
clinical trials | 24 |
odds ratio | 24 |
significantly associated | 24 |
mg day | 24 |
social distancing | 24 |
azelastine nasal | 24 |
chest ct | 24 |
living alone | 24 |
clinical improvement | 24 |
may cause | 23 |
patch test | 23 |
mutual information | 23 |
ige mediated | 23 |
two weeks | 23 |
respiratory disease | 23 |
symptom count | 23 |
asthma exacerbations | 23 |
anaphylactic reaction | 23 |
bone marrow | 23 |
drug allergy | 23 |
provocation test | 23 |
one patient | 23 |
sample size | 23 |
cohort study | 23 |
statistical significance | 23 |
associated factors | 23 |
per year | 23 |
asthma patients | 22 |
related factors | 22 |
allergen immunotherapy | 22 |
within minutes | 22 |
dry cough | 22 |
respiratory infection | 22 |
adverse reactions | 22 |
mg bid | 22 |
cancer patients | 22 |
regression analysis | 22 |
transmission risk | 22 |
pollen allergy | 22 |
contact dermatitis | 22 |
asthma exacerbation | 22 |
rhinitis symptoms | 22 |
allergic rhinoconjunctivitis | 22 |
high prevalence | 22 |
placebo group | 22 |
clinical symptoms | 22 |
results suggest | 22 |
test results | 22 |
nasal mucosa | 22 |
two patients | 22 |
allergic disease | 22 |
older adults | 22 |
pulmonary disease | 22 |
patient reported | 22 |
milk allergy | 22 |
latex allergy | 21 |
significantly increased | 21 |
systemic symptoms | 21 |
challenge test | 21 |
less likely | 21 |
nasal discharge | 21 |
distress tolerance | 21 |
least likely | 21 |
patients without | 21 |
psychological interventions | 21 |
disease control | 21 |
nervous system | 21 |
polymerase chain | 21 |
trauma survivors | 21 |
birch pollen | 21 |
network analysis | 21 |
health symptoms | 21 |
marital status | 21 |
contact frequency | 21 |
clinical trial | 21 |
inhaled corticosteroids | 21 |
age groups | 21 |
every day | 21 |
ptg attributed | 21 |
aged years | 21 |
significantly lower | 21 |
induced asthma | 21 |
pregnant women | 20 |
otitis media | 20 |
chronic obstructive | 20 |
obstructive pulmonary | 20 |
children aged | 20 |
first case | 20 |
longitudinal study | 20 |
chart review | 20 |
significant increase | 20 |
hubei province | 20 |
symptomatic exacerbation | 20 |
medication use | 20 |
nasal polyps | 20 |
physical exam | 20 |
contact tracing | 20 |
severe symptoms | 20 |
cd cells | 20 |
allergen exposure | 20 |
controlled trial | 20 |
family members | 20 |
positive results | 20 |
major allergen | 20 |
chest tightness | 20 |
common variable | 20 |
young children | 20 |
type i | 20 |
inject drugs | 20 |
peer review | 20 |
may help | 20 |
adult patients | 20 |
specific symptoms | 20 |
differential diagnosis | 20 |
function tests | 20 |
asthma triggers | 19 |
severe allergic | 19 |
tree nut | 19 |
receptor antagonist | 19 |
age group | 19 |
asthma diagnosis | 19 |
patients may | 19 |
written informed | 19 |
two years | 19 |
per day | 19 |
elderly chinese | 19 |
study population | 19 |
viral culture | 19 |
chronic sinusitis | 19 |
allergy clinic | 19 |
risk group | 19 |
last years | 19 |
safety profile | 19 |
indoor environment | 19 |
effective treatment | 19 |
intensive care | 19 |
flow cytometry | 19 |
among patients | 19 |
clinically relevant | 19 |
like symptoms | 19 |
stochastic progression | 19 |
respiratory distress | 19 |
injection equipment | 19 |
statistical analysis | 19 |
demographic characteristics | 19 |
months later | 19 |
syncytial virus | 19 |
ct scan | 19 |
respiratory syncytial | 19 |
control measures | 19 |
among participants | 18 |
per week | 18 |
ethics committee | 18 |
per person | 18 |
study group | 18 |
hong kong | 18 |
influenza viruses | 18 |
new york | 18 |
may occur | 18 |
hiv transmission | 18 |
patient health | 18 |
patient presented | 18 |
prick testing | 18 |
treatment groups | 18 |
coronavirus pneumonia | 18 |
four patients | 18 |
patients received | 18 |
see table | 18 |
celiac disease | 18 |
longer time | 18 |
chinese population | 18 |
psychiatric disorders | 18 |
distress among | 18 |
mast cells | 18 |
psychopathological symptoms | 18 |
depression scale | 18 |
progression model | 18 |
expiratory flow | 18 |
may affect | 18 |
participants reported | 18 |
ventilation rate | 18 |
covid symptom | 17 |
mean score | 17 |
forced expiratory | 17 |
severe persistent | 17 |
epidemic among | 17 |
drug use | 17 |
classic symptoms | 17 |
tree pollen | 17 |
primary immunodeficiency | 17 |
drug allergies | 17 |
randomized controlled | 17 |
tested positive | 17 |
respiratory failure | 17 |
respiratory viral | 17 |
nasal symptom | 17 |
severe cases | 17 |
pediatric patients | 17 |
asthmatic individuals | 17 |
symptom study | 17 |
intranasal steroids | 17 |
physical health | 17 |
cutoff score | 17 |
first time | 17 |
breast cancer | 17 |
one month | 17 |
treated patients | 17 |
patients presenting | 17 |
building materials | 17 |
blocked nose | 17 |
positive patients | 17 |
categorical variables | 17 |
previously reported | 17 |
serum levels | 17 |
nasal blockage | 17 |
total number | 17 |
within normal | 17 |
cat allergen | 17 |
i think | 16 |
normal range | 16 |
allergic conjunctivitis | 16 |
depression among | 16 |
asthmatic children | 16 |
clinical diagnosis | 16 |
significantly greater | 16 |
infected patients | 16 |
skin lesions | 16 |
rapid detection | 16 |
seed word | 16 |
clinical history | 16 |
patient developed | 16 |
environmental factors | 16 |
high school | 16 |
variable immunodeficiency | 16 |
general public | 16 |
case reports | 16 |
skin biopsy | 16 |
first symptom | 16 |
mild asthma | 16 |
significant correlation | 16 |
retrospective study | 16 |
inclusion criteria | 16 |
pollen counts | 16 |
syndrome coronavirus | 16 |
seasonal influenza | 16 |
patients reported | 16 |
antibiotic therapy | 16 |
chronic disease | 16 |
pediatric migraine | 16 |
ventilation rates | 16 |
oral challenge | 16 |
one week | 16 |
allergen challenge | 16 |
allergy testing | 16 |
prospective study | 16 |
infectious disease | 16 |
significant improvement | 16 |
health questionnaire | 16 |
significantly improved | 16 |
acid reflux | 16 |
single dose | 16 |
many patients | 16 |
wide range | 16 |
cd high | 16 |
gastroesophageal reflux | 16 |
twice daily | 16 |
cat dander | 16 |
diagnostic tests | 16 |
condomless sex | 16 |
laboratory data | 16 |
atopic patients | 16 |
adverse reaction | 16 |
nasal obstruction | 16 |
rhinitis patients | 16 |
blood count | 16 |
healthy subjects | 15 |
peak expiratory | 15 |
common symptoms | 15 |
influenza infection | 15 |
standard deviation | 15 |
old man | 15 |
severity index | 15 |
expiratory volume | 15 |
allergic contact | 15 |
hypersensitivity reaction | 15 |
occupational asthma | 15 |
within hours | 15 |
hiv infection | 15 |
symptoms compared | 15 |
sublingual immunotherapy | 15 |
among chinese | 15 |
patients receiving | 15 |
generalized urticaria | 15 |
early symptoms | 15 |
volatile organic | 15 |
long term | 15 |
common cause | 15 |
anaphylactic reactions | 15 |
patients presented | 15 |
allergic sensitization | 15 |
findings suggest | 15 |
posted may | 15 |
time point | 15 |
viral respiratory | 15 |
first day | 15 |
office workers | 15 |
prophylactic antibiotics | 15 |
observational study | 15 |
health outcomes | 15 |
close contact | 15 |
desensitization protocol | 15 |
may lead | 15 |
transition probabilities | 15 |
suicidal thoughts | 15 |
body mass | 15 |
nut allergy | 15 |
significant reduction | 15 |
clinical course | 15 |
recent studies | 15 |
peak stage | 15 |
peak flow | 15 |
control subjects | 15 |
tract infection | 15 |
weight loss | 15 |
sleep quality | 15 |
may result | 15 |
air pollutants | 15 |
old boy | 15 |
year history | 15 |
ige antibodies | 15 |
predictive value | 15 |
asthma prevalence | 14 |
cow milk | 14 |
medical records | 14 |
patch tests | 14 |
mg qd | 14 |
clinical presentation | 14 |
purulent sputum | 14 |
significant association | 14 |
mass index | 14 |
psychological outcomes | 14 |
symptomatic exacerbations | 14 |
incubation period | 14 |
authors declare | 14 |
two months | 14 |
natural history | 14 |
commonly reported | 14 |
recurrent infections | 14 |
muscle pain | 14 |
demographic data | 14 |
education level | 14 |
first year | 14 |
data regarding | 14 |
clinical efficacy | 14 |
online survey | 14 |
close others | 14 |
response rate | 14 |
continuous variables | 14 |
au ml | 14 |
perceived health | 14 |
chronic rhinosinusitis | 14 |
free diet | 14 |
confidence interval | 14 |
nitric oxide | 14 |
widely used | 14 |
sectional survey | 14 |
bridge symptoms | 14 |
three months | 14 |
allergy symptoms | 14 |
food challenge | 14 |
higher prevalence | 14 |
immune deficiency | 14 |
anxiety disorders | 14 |
analysis revealed | 14 |
serum tryptase | 14 |
gender differences | 14 |
lung cancer | 14 |
also found | 14 |
histamine release | 14 |
vital signs | 14 |
chronic diseases | 14 |
adverse effects | 14 |
trigger asthma | 14 |
respondents reported | 14 |
emergency room | 13 |
among students | 13 |
antiviral treatment | 13 |
significantly reduced | 13 |
viral shedding | 13 |
patients using | 13 |
family member | 13 |
controlled study | 13 |
th day | 13 |
specific antibody | 13 |
high fever | 13 |
maintenance dose | 13 |
among pwid | 13 |
supplementary material | 13 |
patients showed | 13 |
medrxiv preprint | 13 |
treatment period | 13 |
respiratory health | 13 |
patients suffering | 13 |
per month | 13 |
normal limits | 13 |
important role | 13 |
serum total | 13 |
reactive protein | 13 |
control study | 13 |
determine whether | 13 |
clinical manifestations | 13 |
infectious diseases | 13 |
without digestive | 13 |
disease severity | 13 |
immediate psychological | 13 |
upper airway | 13 |
distress related | 13 |
poor metabolizers | 13 |
infection control | 13 |
perennial allergic | 13 |
cough features | 13 |
psychological responses | 13 |
evaluation revealed | 13 |
initial symptoms | 13 |
days later | 13 |
psychological education | 13 |
bridge centrality | 13 |
consecutive days | 13 |
injectable epinephrine | 13 |
positive nf | 13 |
background characteristics | 13 |
several studies | 13 |
severe atopic | 13 |
sexual risk | 13 |
blood pressure | 13 |
ocular symptoms | 13 |
confirmed covid | 13 |
included patients | 13 |
analysis showed | 13 |
allergic response | 13 |
last year | 13 |
study aimed | 13 |
assessed using | 13 |
central nervous | 13 |
symptoms amongst | 13 |
symptoms including | 13 |
childhood asthma | 13 |
pollen allergic | 13 |
every months | 13 |
tract symptoms | 13 |
acting beta | 13 |
one study | 13 |
serum specific | 13 |
chronic rhinitis | 13 |
patients underwent | 13 |
health services | 13 |
medical conditions | 13 |
oral food | 13 |
cold symptoms | 13 |
outbreak stage | 13 |
body temperature | 13 |
retrospective chart | 13 |
air pollution | 12 |
control groups | 12 |
allergy asthma | 12 |
environmental control | 12 |
patients aged | 12 |
cumulative total | 12 |
induced anaphylaxis | 12 |
airway obstruction | 12 |
frequently reported | 12 |
milk protein | 12 |
systemic reactions | 12 |
previous research | 12 |
disease course | 12 |
lymph nodes | 12 |
mrna expression | 12 |
allergen components | 12 |
primary symptoms | 12 |
cell count | 12 |
mass spectrometry | 12 |
higher scores | 12 |
symptom relations | 12 |
health consequences | 12 |
respiratory illnesses | 12 |
moderate asthma | 12 |
two different | 12 |
medical concepts | 12 |
among people | 12 |
pediatric population | 12 |
complete blood | 12 |
clinical outcomes | 12 |
asthma immunology | 12 |
medical center | 12 |
peanut allergens | 12 |
indoor environments | 12 |
symptoms intensity | 12 |
organic compounds | 12 |
daily activities | 12 |
symptoms associated | 12 |
likely paths | 12 |
blood vessels | 12 |
fungal spores | 12 |
clinical response | 12 |
asthma medication | 12 |
linear regression | 12 |
cough sounds | 12 |
reg cd | 12 |
days vs | 12 |
intradermal skin | 12 |
three times | 12 |
intradermal testing | 12 |
quarantine guidelines | 12 |
reduced olfaction | 12 |
regression models | 12 |
point scale | 12 |
indoor environmental | 12 |
healthy control | 12 |
chronic fatigue | 12 |
old caucasian | 12 |
time course | 12 |
ed visits | 12 |
care unit | 12 |
laboratory tests | 12 |
male patient | 12 |
peak stages | 12 |
six months | 12 |
severe depression | 12 |
likert scale | 12 |
impaired motor | 12 |
significantly different | 12 |
lung disease | 12 |
much higher | 12 |
first week | 12 |
pilot study | 12 |
lower airway | 12 |
using spss | 12 |
fluticasone propionate | 12 |
streptococcus pneumoniae | 12 |
united kingdom | 12 |
study protocol | 12 |
conditional mutual | 12 |
study participants | 12 |
physical disease | 12 |
almost never | 12 |
traumatic event | 12 |
posted april | 11 |
staphylococcus aureus | 11 |
serum level | 11 |
natural killer | 11 |
perceived social | 11 |
reflux disorders | 11 |
positive correlation | 11 |
gastrointestinal tract | 11 |
sars outbreak | 11 |
medical care | 11 |
acute attacks | 11 |
three years | 11 |
systemic steroids | 11 |
low cd | 11 |
observation group | 11 |
inflammatory mediators | 11 |
without gi | 11 |
reverse transcription | 11 |
alcohol consumption | 11 |
major allergens | 11 |
blood eosinophilia | 11 |
chinese people | 11 |
guinea pigs | 11 |
language processing | 11 |
personal protective | 11 |
elite athletes | 11 |
initial stage | 11 |
psychiatric symptoms | 11 |
neural networks | 11 |
psychological symptoms | 11 |
ragweed pollen | 11 |
psychological effects | 11 |
monoclonal antibody | 11 |
testing positive | 11 |
symptoms include | 11 |
study showed | 11 |
risk behavior | 11 |
two hours | 11 |
double blind | 11 |
conducted using | 11 |
allergy syndrome | 11 |
increased levels | 11 |
healthy volunteers | 11 |
nasal secretions | 11 |
high dose | 11 |
even though | 11 |
instrumental support | 11 |
results indicate | 11 |
one hand | 11 |
symptoms experienced | 11 |
acute phase | 11 |
mean scores | 11 |
physical activity | 11 |
dermatophagoides pteronyssinus | 11 |
determined using | 11 |
outdoor air | 11 |
nasal polyposis | 11 |
western blot | 11 |
different types | 11 |
fev fvc | 11 |
phase ii | 11 |
elevated levels | 11 |
scale ranging | 11 |
positive spt | 11 |
physical exercise | 11 |
enzyme immunoassay | 11 |
protective equipment | 11 |
asthmatic subjects | 11 |
lip swelling | 11 |
old white | 11 |
seminal fluid | 11 |
weeks later | 11 |
ct scans | 11 |
older people | 11 |
cystic fibrosis | 11 |
hospital admission | 11 |
middle east | 11 |
inflammatory cells | 11 |
three groups | 11 |
well known | 11 |
significant effect | 11 |
lower levels | 11 |
nk cell | 11 |
adverse drug | 11 |
lower airways | 11 |
biopsy revealed | 11 |
high level | 11 |
relatively low | 11 |
may contribute | 11 |
oral allergy | 11 |
multivariate logistic | 11 |
better understand | 11 |
pediatric subjects | 11 |
also performed | 11 |
reported anxiety | 11 |
nasal itching | 11 |
continuous traumatic | 11 |
pcn skin | 11 |
past medical | 11 |
clinical studies | 11 |
common colds | 11 |
school children | 11 |
molecular weight | 11 |
hyposmia anosmia | 11 |
individuals exposed | 11 |
negative predictive | 11 |
infl uenza | 11 |
first dose | 11 |
diagnostic testing | 11 |
university hospital | 11 |
computed tomography | 11 |
exhaled nitric | 11 |
necrosis factor | 10 |
blood tests | 10 |
within days | 10 |
skin tested | 10 |
chronic cough | 10 |
heart disease | 10 |
previous study | 10 |
second wave | 10 |
questionnaire survey | 10 |
coronavirus outbreak | 10 |
close contacts | 10 |
immunoglobulin levels | 10 |
mg dose | 10 |
ophthalmic solution | 10 |
patients completed | 10 |
itchy nose | 10 |
white male | 10 |
symptom management | 10 |
tobacco smoke | 10 |
receptor antagonists | 10 |
controlled trials | 10 |
increased prevalence | 10 |
past two | 10 |
younger age | 10 |
health disturbances | 10 |
respiratory virus | 10 |
culture medium | 10 |
statistical analyses | 10 |
beclomethasone dipropionate | 10 |
bacterial pneumonia | 10 |
state anxiety | 10 |
milk proteins | 10 |
case illustrates | 10 |
patients infected | 10 |
future studies | 10 |
gi tract | 10 |
rhinovirus infection | 10 |
real time | 10 |
oral steroids | 10 |
outcome measures | 10 |
oral antihistamines | 10 |
total cost | 10 |
epidemic period | 10 |
female patient | 10 |
fev vc | 10 |
based study | 10 |
health professionals | 10 |
mouse model | 10 |
pollen extract | 10 |
exclusion criteria | 10 |
time since | 10 |
oral provocation | 10 |
serum concentrations | 10 |
severe ad | 10 |
outpatient clinic | 10 |
controlled asthma | 10 |
healthcare professionals | 10 |
symptoms subsequent | 10 |
oral antibiotic | 10 |
related quality | 10 |
boolean variables | 10 |
overall prevalence | 10 |
isi scores | 10 |
national health | 10 |
study demonstrated | 10 |
total sample | 10 |
age years | 10 |
missing data | 10 |
clinical picture | 10 |
reflux disease | 10 |
bacterial infections | 10 |
peach tree | 10 |
nebulized ics | 10 |
higher stress | 10 |
symptom levels | 10 |
health effects | 10 |
potential risk | 10 |
illness onset | 10 |
natural language | 10 |
simulated patients | 10 |
several weeks | 10 |
topical steroids | 10 |
appropriate use | 10 |
soc levels | 10 |
oral corticosteroids | 10 |
influenza season | 10 |
reported symptom | 10 |
test result | 10 |
younger people | 10 |
patients diagnosed | 10 |
positive coping | 10 |
drug reaction | 10 |
common symptom | 10 |
small number | 10 |
basophil activation | 10 |
studies suggest | 10 |
allergic subjects | 10 |
old girl | 10 |
east respiratory | 10 |
severe anxiety | 10 |
among older | 10 |
study design | 10 |
connective tissue | 10 |
pollen exposure | 10 |
uncontrolled asthma | 10 |
inflammatory response | 10 |
allergic children | 10 |
immune responses | 10 |
daily symptoms | 10 |
gamma ifn | 10 |
treatment group | 10 |
early diagnosis | 10 |
infected pneumonia | 10 |
prednisone mg | 10 |
type ii | 10 |
allergen extracts | 10 |
data suggest | 10 |
point likert | 10 |
symptomatic treatment | 10 |
general lockdown | 10 |
yellow fever | 10 |
ventilation systems | 10 |
symptom changes | 10 |
reported outcomes | 10 |
nasal allergy | 10 |
allergy unit | 10 |
data analysis | 10 |
descriptive study | 10 |
symptoms report | 10 |
positive test | 10 |
findings may | 10 |
may provide | 10 |
somatization subscores | 10 |
new symptoms | 10 |
ocular itching | 10 |
elevated anxiety | 10 |
sedating antihistamines | 10 |
also reported | 10 |
past months | 10 |
related airway | 10 |
every weeks | 10 |
first step | 10 |
chronic inflammation | 10 |
months prior | 10 |
four weeks | 10 |
sharing injection | 10 |
healthy individuals | 10 |
statistical differences | 10 |
significant decrease | 10 |
psychometric properties | 10 |
hours later | 10 |
complete resolution | 10 |
mononuclear cells | 10 |
posted november | 10 |
primary endpoint | 10 |
injection drug | 10 |
analyzed using | 10 |
higher among | 10 |
asthma care | 10 |
food sensitization | 10 |
commercially available | 10 |
machine learning | 9 |
health conditions | 9 |
patient data | 9 |
structural models | 9 |
sudden death | 9 |
patients experienced | 9 |
alternaria alternata | 9 |
viral load | 9 |
total protein | 9 |
ar patients | 9 |
rights reserved | 9 |
gluten free | 9 |
related stress | 9 |
exacerbation episode | 9 |
disease outbreak | 9 |
african american | 9 |
one second | 9 |
fever positive | 9 |
cd count | 9 |
results showed | 9 |
diagnostic criteria | 9 |
unknown etiology | 9 |
cold air | 9 |
internal consistency | 9 |
older parents | 9 |
tissue eosinophilia | 9 |
allowed without | 9 |
chi square | 9 |
common food | 9 |
two symptoms | 9 |
medical articles | 9 |
supplemental table | 9 |
diagnostic test | 9 |
first days | 9 |
tnfsf light | 9 |
greater risk | 9 |
corticosteroid therapy | 9 |
elderly patients | 9 |
hypersensitivity pneumonitis | 9 |
negative skin | 9 |
cytokine production | 9 |
airway remodeling | 9 |
local reactions | 9 |
first two | 9 |
pollen allergens | 9 |
three days | 9 |
risk assessment | 9 |
bacterial infection | 9 |
serum igg | 9 |
provocation tests | 9 |
group compared | 9 |
times daily | 9 |
correlation analysis | 9 |
unique contribution | 9 |
eye symptoms | 9 |
symptoms reported | 9 |
informative symptoms | 9 |
inflammatory diseases | 9 |
might also | 9 |
male presented | 9 |
hae patients | 9 |
ige reactivity | 9 |
insomnia severity | 9 |
nf swabs | 9 |
family support | 9 |
ige igg | 9 |
allergic inflammation | 9 |
marginal structural | 9 |
may play | 9 |
airway epithelial | 9 |
among healthcare | 9 |
regression analyses | 9 |
qualitative study | 9 |
informative symptom | 9 |
positive hcws | 9 |
egg allergy | 9 |
discernible symptoms | 9 |
low igg | 9 |
ui ml | 9 |
one symptom | 9 |
higher proportion | 9 |
airway hyperresponsiveness | 9 |
psychomotor symptoms | 9 |
without asthma | 9 |
anaphylactic shock | 9 |
inhaled corticosteroid | 9 |
granulomatous disease | 9 |
patients also | 9 |
successful desensitization | 9 |
respiratory rate | 9 |
mean total | 9 |
oral ulcers | 9 |
clinical relevance | 9 |
ragweed season | 9 |
current covid | 9 |
subjects allergic | 9 |
lockdown conditions | 9 |
sleep problems | 9 |
care provider | 9 |
mg daily | 9 |
statistically significantly | 9 |
azelastine hydrochloride | 9 |
female gender | 9 |
pimecrolimus cream | 9 |
negative results | 9 |
total serum | 9 |
equipment sharing | 9 |
motor skills | 9 |
among individuals | 9 |
behaviors among | 9 |
reuse allowed | 9 |
relevant changes | 9 |
global health | 9 |
among medical | 9 |
negative impact | 9 |
infected individuals | 9 |
mg infusion | 9 |
medical diagnosis | 9 |
mometasone furoate | 9 |
among children | 9 |
causal relationship | 9 |
allergic airway | 9 |
diagnostic delay | 9 |
mold spores | 9 |
specific antibodies | 9 |
life questionnaire | 9 |
normal levels | 9 |
group showed | 9 |
amc lev | 9 |
fold increase | 9 |
renal failure | 9 |
initial symptom | 9 |
cancer care | 9 |
mucous membrane | 9 |
negative control | 9 |
traumatic distress | 9 |
clinical signs | 9 |
without permission | 9 |
common mental | 9 |
challenge tests | 9 |
igg antibodies | 9 |
less common | 9 |
medical professionals | 9 |
coping style | 9 |
visual analogue | 9 |
delta crud | 9 |
asthma attacks | 9 |
several days | 9 |
asthma medications | 9 |
gastrointestinal manifestations | 9 |
atopic asthma | 9 |
subcutaneous immunotherapy | 9 |
prior studies | 9 |
first symptoms | 9 |
new orleans | 9 |
fexofenadine hcl | 9 |
nucleic acid | 9 |
years ago | 9 |
oral tolerance | 9 |
building occupants | 9 |
replacement therapy | 9 |
five days | 9 |
otherwise healthy | 9 |
relatively high | 9 |
skin rash | 9 |
source control | 9 |
eosinophil counts | 9 |
also negative | 8 |
patients will | 8 |
study medication | 8 |
ill patients | 8 |
clinically meaningful | 8 |
inflammatory markers | 8 |
closely related | 8 |
among college | 8 |
million people | 8 |
may reduce | 8 |
vast majority | 8 |
negative emotions | 8 |
suspected cases | 8 |
vital capacity | 8 |
innate immunity | 8 |
general practitioners | 8 |
block consisted | 8 |
induced bronchoconstriction | 8 |
york city | 8 |
clinical settings | 8 |
current asthma | 8 |
adult subjects | 8 |
symptoms like | 8 |
several limitations | 8 |
reduced sense | 8 |
past history | 8 |
watery eyes | 8 |
patients reporting | 8 |
pcg ml | 8 |
lockdown phase | 8 |
last months | 8 |
pts symptoms | 8 |
patients allergic | 8 |
diabetes mellitus | 8 |
oral immunotherapy | 8 |
network properties | 8 |
sensitivity analyses | 8 |
corona virus | 8 |
similar results | 8 |
bmp serum | 8 |
tests showed | 8 |
hay fever | 8 |
time pcr | 8 |
whole body | 8 |
mite allergen | 8 |
smell taste | 8 |
probably due | 8 |
full text | 8 |
results demonstrate | 8 |
retrospective analysis | 8 |
epidemiological study | 8 |
drug reactions | 8 |
relatively small | 8 |
interquartile range | 8 |
direct contact | 8 |
holdout sample | 8 |
severe disease | 8 |
oh dl | 8 |
symptom control | 8 |
ventilation system | 8 |
tested negative | 8 |
epidemiologic studies | 8 |
airway disorders | 8 |
damaged buildings | 8 |
proinflammatory cytokines | 8 |
perennial rhinitis | 8 |
lymph node | 8 |
nasal epithelium | 8 |
ics therapy | 8 |
depressive disorders | 8 |
univariate analysis | 8 |
sinus surgery | 8 |
never confiding | 8 |
laboratory findings | 8 |
esterase inhibitor | 8 |
converting enzyme | 8 |
several months | 8 |
edge weights | 8 |
threshold dose | 8 |
eosinophilic infiltration | 8 |
severe reactions | 8 |
patients referred | 8 |
total nasal | 8 |
least days | 8 |
disease may | 8 |
individual symptom | 8 |
influenza outbreak | 8 |
antibiotic treatment | 8 |
control test | 8 |
blood eosinophil | 8 |
chronic inflammatory | 8 |
normally distributed | 8 |
online suppl | 8 |
subscale score | 8 |
positive reaction | 8 |
patients experience | 8 |
psychological resilience | 8 |
medical treatment | 8 |
pleural effusion | 8 |
protective factor | 8 |
symptom detection | 8 |
sensitized patients | 8 |
line medical | 8 |
also observed | 8 |
trigeminal nerves | 8 |
positive reactions | 8 |
binding capacity | 8 |
eight patients | 8 |
oral desensitization | 8 |
hereditary angioedema | 8 |
mg bd | 8 |
igg subclass | 8 |
approximately one | 8 |
tests revealed | 8 |
grass tablets | 8 |
hospital admissions | 8 |
symptoms using | 8 |
food products | 8 |
elevated peritraumatic | 8 |
specific treatment | 8 |
preterm birth | 8 |
platelet count | 8 |
asthma management | 8 |
one hour | 8 |
final visit | 8 |
study included | 8 |
ptsd checklist | 8 |
psychological stress | 8 |
related traumatic | 8 |
treatment discontinuation | 8 |
mental illness | 8 |
confirmed influenza | 8 |
heart failure | 8 |
correct diagnosis | 8 |
nk cells | 8 |
healthcare system | 8 |
multiple sclerosis | 8 |
mcg dl | 8 |
cumulative dose | 8 |
female presented | 8 |
nearly every | 8 |
also significantly | 8 |
mean change | 8 |
risk patients | 8 |
fi rst | 8 |
never almost | 8 |
studies reported | 8 |
respiratory illness | 8 |
european countries | 8 |
months old | 8 |
clinical findings | 8 |
severe forms | 8 |
symptoms within | 8 |
cell line | 8 |
virus infections | 8 |
explaining peritraumatic | 8 |
will help | 8 |
dependent exercise | 8 |
flu jab | 8 |
fatigue syndrome | 8 |
may develop | 8 |
without concomitant | 8 |
clinical significance | 8 |
clinically stable | 8 |
mean duration | 8 |
cross reactivity | 8 |
local data | 8 |
aged children | 8 |
patients tested | 8 |
mediated cytotoxicity | 8 |
chronic asthma | 8 |
consent form | 8 |
may experience | 8 |
positive response | 8 |
ige synthesis | 8 |
independent variables | 8 |
oral roflumilast | 8 |
severe reaction | 8 |
creative commons | 8 |
may reflect | 8 |
symptoms included | 8 |
patient education | 8 |
data collected | 8 |
results show | 8 |
three patients | 8 |
prevalence rates | 8 |
descriptive statistics | 8 |
also used | 8 |
distress syndrome | 8 |
symptom network | 8 |
social isolation | 8 |
cervical lymphadenopathy | 8 |
adult children | 8 |
immunocap isac | 8 |
psychological health | 8 |
hcl mg | 8 |
average income | 8 |
systemic corticosteroids | 8 |
extremely rare | 8 |
northern italy | 8 |
clinical evaluation | 8 |
respiratory system | 8 |
study days | 8 |
lower rates | 8 |
influenza test | 8 |
five patients | 8 |
thrombin generation | 8 |
initial evaluation | 8 |
rural areas | 8 |
football players | 8 |
first study | 8 |
high concentrations | 8 |
also known | 8 |
nasal provocation | 8 |
patient received | 8 |
recent years | 8 |
exercise induced | 8 |
blind placebo | 8 |
commercial extracts | 8 |
statistical difference | 8 |
copd patients | 8 |
work environment | 8 |
influencing factors | 8 |
study using | 8 |
natural ventilation | 8 |
intermittent asthma | 8 |
reported experiencing | 8 |
erythema multiforme | 8 |
acute upper | 8 |
carrageenan group | 8 |
three consecutive | 8 |
also showed | 8 |
neural network | 8 |
food allergic | 8 |
health authorities | 8 |
productive cough | 8 |
lymphocyte count | 8 |
pnu ml | 8 |
clinical data | 7 |
conducted among | 7 |
chinese elderly | 7 |
nationwide survey | 7 |
coronavirus infection | 7 |
also may | 7 |
rapid review | 7 |
sensitive asthmatic | 7 |
infection may | 7 |
related complications | 7 |
allergen specific | 7 |
times higher | 7 |
repertoire diversity | 7 |
dose response | 7 |
male respondents | 7 |
item versions | 7 |
indoor pollutants | 7 |
protective effect | 7 |
geographic area | 7 |
drug therapy | 7 |
study suggests | 7 |
frequent fliers | 7 |
sds bmi | 7 |
significantly decreased | 7 |
blood samples | 7 |
cypress pollen | 7 |
amino acid | 7 |
prospective cohort | 7 |
sudden onset | 7 |
extremely severe | 7 |
human beings | 7 |
suspected influenza | 7 |
group i | 7 |
symptoms occurred | 7 |
dry eye | 7 |
group ii | 7 |
host cell | 7 |
caucasian male | 7 |
increased incidence | 7 |
heart rate | 7 |
clinical implications | 7 |
maculopapular rash | 7 |
immune cells | 7 |
closely linked | 7 |
eosinophilic esophagitis | 7 |
mild intermittent | 7 |
review board | 7 |
highly contagious | 7 |
hymenoptera venom | 7 |
user guide | 7 |
sickle cell | 7 |
may increase | 7 |
psychological support | 7 |
additional stressor | 7 |
elisa inhibition | 7 |
pwid living | 7 |
analogue scale | 7 |
takayasu arteritis | 7 |
systemic reaction | 7 |
immunology clinic | 7 |
measured via | 7 |
less frequent | 7 |
diagnostic tool | 7 |
gustatory dysfunction | 7 |
case management | 7 |
fever negative | 7 |
ocs users | 7 |
thoracic society | 7 |
cumulative number | 7 |
prevention measures | 7 |
early onset | 7 |
serum albumin | 7 |
molecular mass | 7 |
biopsy showed | 7 |
laboratory evaluation | 7 |
nasal lavage | 7 |
among workers | 7 |
epithelial cell | 7 |
without treatment | 7 |
also associated | 7 |
opn levels | 7 |
mucous membranes | 7 |
antiviral therapy | 7 |
asthma education | 7 |
additional stressors | 7 |
systemic therapy | 7 |
symptoms onset | 7 |
lower risk | 7 |
report high | 7 |
guinea pig | 7 |
past month | 7 |
causation entropy | 7 |
healthcare institutions | 7 |
protein levels | 7 |
inhaled steroids | 7 |
study reported | 7 |
anaphylaxis due | 7 |
hospitalised patients | 7 |
autoimmune diseases | 7 |
specific symptom | 7 |
poor quality | 7 |
publicly available | 7 |
white blood | 7 |
igg subclasses | 7 |
showed increased | 7 |
inflammatory cytokines | 7 |
evaluated using | 7 |
patients admitted | 7 |
treatment option | 7 |
kg day | 7 |
nan doi | 7 |
early stage | 7 |
two studies | 7 |
health service | 7 |
respiratory conditions | 7 |
pulmonary symptoms | 7 |
nonsedating antihistamines | 7 |
primary outcome | 7 |
many cases | 7 |
hdm slit | 7 |
psychosocial factors | 7 |
children may | 7 |
five percent | 7 |
allergic disorders | 7 |
thai nguyen | 7 |
independently associated | 7 |
essential hypertension | 7 |
patients hospitalized | 7 |
ipratropium bromide | 7 |
virus types | 7 |
decreased significantly | 7 |
student status | 7 |
associated symptoms | 7 |
symptom improvement | 7 |
symptom relief | 7 |
risk asthmatics | 7 |
treat asthma | 7 |
worsening symptoms | 7 |
primary schools | 7 |
tmp smx | 7 |
considered statistically | 7 |
female respondents | 7 |
positive prick | 7 |
elimination diet | 7 |
versus placebo | 7 |
high rates | 7 |
pork meat | 7 |
patients sensitized | 7 |
unscheduled office | 7 |
ml vs | 7 |
fully adjusted | 7 |
distress outcomes | 7 |
air conditioning | 7 |
three different | 7 |
previous diagnosis | 7 |
increased significantly | 7 |
wheat flour | 7 |
nonsedating agents | 7 |
asymptomatic patients | 7 |
last day | 7 |
study demonstrates | 7 |
rescue medication | 7 |
every hours | 7 |
gold standard | 7 |
higher level | 7 |
adults may | 7 |
patient care | 7 |
among hospitalized | 7 |
findings indicated | 7 |
elevated serum | 7 |
early symptom | 7 |
high incidence | 7 |
treatment options | 7 |
common aeroallergens | 7 |
treatment periods | 7 |
symptoms severity | 7 |
important factor | 7 |
digestive system | 7 |
additional information | 7 |
negative nf | 7 |
italian population | 7 |
representative embedding | 7 |
common allergens | 7 |
recurrent episodes | 7 |
mite allergens | 7 |
positively correlated | 7 |
showed positive | 7 |
frequently used | 7 |
human metapneumovirus | 7 |
chronic respiratory | 7 |
four times | 7 |
multicenter study | 7 |
individual symptoms | 7 |
built environment | 7 |
anxiety group | 7 |
cold viruses | 7 |
recommended doses | 7 |
nerve dysfunction | 7 |
patients included | 7 |
cell function | 7 |
may show | 7 |
viral pneumonia | 7 |
occupational health | 7 |
negative alterations | 7 |
nasal secretion | 7 |
medication scores | 7 |
free text | 7 |
recurrent sinusitis | 7 |
phase response | 7 |
elderly persons | 7 |
first months | 7 |
studies conducted | 7 |
question generation | 7 |
stress scale | 7 |
allergy clin | 7 |
among young | 7 |
positive predictive | 7 |
psychological knowledge | 7 |
asthma therapy | 7 |
neuropsychiatric symptoms | 7 |
prediction models | 7 |
study aims | 7 |
intradermal tests | 7 |
antibody responses | 7 |
cortisol levels | 7 |
relevant symptoms | 7 |
mild persistent | 7 |
medical literature | 7 |
longitudinal studies | 7 |
may require | 7 |
online questionnaire | 7 |
acquired pneumonia | 7 |
results indicated | 7 |
table shows | 7 |
selection bias | 7 |
disease characterized | 7 |
significant associations | 7 |
environmental quality | 7 |
case records | 7 |
performed skin | 7 |
negative effects | 7 |
often associated | 7 |
care setting | 7 |
antibody response | 7 |
per nostril | 7 |
developing depressive | 7 |
mechanical ventilation | 7 |
similar symptoms | 7 |
antibody deficiency | 7 |
two treatment | 7 |
economic loss | 7 |
stress symptom | 7 |
patient experienced | 7 |
mild depressive | 7 |
pcn allergy | 7 |
oral mucosa | 7 |
data curation | 7 |
multivariable logistic | 7 |
including asthma | 7 |
folic acid | 7 |
clin immunol | 7 |
present case | 7 |
aspergillus fumigatus | 7 |
one case | 7 |
myocardial infarction | 7 |
positive swab | 7 |
positive cases | 7 |
adhesion molecule | 7 |
coping styles | 7 |
mycoplasma pneumoniae | 7 |
square test | 7 |
current pandemic | 7 |
questionnaire respondents | 7 |
year period | 7 |
ethical approval | 7 |
high resolution | 7 |
china health | 7 |
index case | 7 |
depressive symptom | 7 |
sectional design | 7 |
immunologic evaluation | 7 |
study drug | 7 |
fish allergic | 7 |
dominant factors | 7 |
lung tissue | 7 |
test showed | 7 |
age range | 7 |
longitudinal effect | 7 |
low level | 7 |
mm wheal | 7 |
adult onset | 7 |
office environment | 7 |
environmental exposure | 7 |
nasopharyngeal swabs | 7 |
scan showed | 7 |
spain background | 7 |
cell degranulation | 7 |
baked milk | 7 |
psychological well | 7 |
three weeks | 7 |
mcg ml | 7 |
month old | 7 |
hr post | 7 |
green pepper | 7 |
symptoms might | 7 |
pollen grains | 7 |
immunocompromised patients | 7 |
nucleic acids | 7 |
study found | 7 |
phrenic nerve | 7 |
blood eosinophils | 7 |
significantly less | 7 |
gel electrophoresis | 7 |
additional file | 7 |
participants provided | 7 |
time spent | 7 |
nasopharyngeal swab | 7 |
following criteria | 7 |
serious adverse | 7 |
primary efficacy | 7 |
chronic medical | 7 |
lactam allergy | 7 |
assessing generalized | 7 |
several factors | 7 |
recurrent respiratory | 7 |
early detection | 7 |
disease progression | 7 |
egg yolk | 7 |
school education | 7 |
beyond background | 7 |
pollen extracts | 7 |
controller medication | 7 |
antiviral agents | 7 |
future research | 7 |
early recognition | 7 |
different symptoms | 7 |
increasing number | 7 |
may include | 7 |
preventive measures | 7 |
phase iii | 7 |
polysensitized patients | 7 |
mean serum | 7 |
poor metabolizer | 7 |
citizen science | 7 |
seasonal rhinitis | 6 |
pollen sensitization | 6 |
ige concentration | 6 |
health emergency | 6 |
south limburg | 6 |
prospective studies | 6 |
urgently needed | 6 |
symptoms increased | 6 |
clinical care | 6 |
inflammatory cytokine | 6 |
data set | 6 |
statistical manual | 6 |
children treated | 6 |
convenience sample | 6 |
killer cells | 6 |
past years | 6 |
monoclonal antibodies | 6 |
anti ige | 6 |
fl uid | 6 |
north america | 6 |
sinus pain | 6 |
disorder symptoms | 6 |
symptom checklist | 6 |
patients suffered | 6 |
patients whose | 6 |
symptom occurrence | 6 |
resolved within | 6 |
controller therapy | 6 |
first patient | 6 |
study data | 6 |
rapid influenza | 6 |
healthy children | 6 |
natural disasters | 6 |
life events | 6 |
allergy management | 6 |
two cases | 6 |
recent study | 6 |
medication score | 6 |
significantly longer | 6 |
directigen flu | 6 |
broad spectrum | 6 |
symptoms progression | 6 |
asymptomatic infections | 6 |
intranasal corticosteroids | 6 |
data format | 6 |
symptoms resolved | 6 |
causative agents | 6 |
hand hygiene | 6 |
blood cell | 6 |
artificial intelligence | 6 |
item version | 6 |
mean difference | 6 |
penicillin skin | 6 |
emergency physicians | 6 |
oral prednisone | 6 |
higher doses | 6 |
placebo controlled | 6 |
somatization group | 6 |
context embedding | 6 |
mechanisms underlying | 6 |
predictively informative | 6 |
sum scores | 6 |
tulobuterol tape | 6 |
leading cause | 6 |
statistical computing | 6 |
facial edema | 6 |
patients older | 6 |
moderately severe | 6 |
prevalence rate | 6 |
severe stress | 6 |
well documented | 6 |
culprit drug | 6 |
isolate system | 6 |
inhibitory effect | 6 |
pollen concentrations | 6 |
still present | 6 |
intradermal test | 6 |
smoking cessation | 6 |
significant peritraumatic | 6 |
complete response | 6 |
positive rate | 6 |
respondents presented | 6 |
skin disease | 6 |
dairy products | 6 |
trauma history | 6 |
iga levels | 6 |
tryptase levels | 6 |
therapy may | 6 |
beneficial effects | 6 |
poor control | 6 |
less severe | 6 |
also asked | 6 |
infected cases | 6 |
study will | 6 |
never getting | 6 |
mediated reactions | 6 |
difficulty breathing | 6 |
also demonstrated | 6 |
simulated patient | 6 |
rarely reported | 6 |
cell deficiency | 6 |
regression model | 6 |
health surveillance | 6 |
systemic diseases | 6 |
worldwide distribution | 6 |
among nigerians | 6 |
different groups | 6 |
university students | 6 |
airways disease | 6 |
nedocromil sodium | 6 |
clinical management | 6 |
pulmonary hypertension | 6 |
office visits | 6 |
mg every | 6 |
brief measure | 6 |
structured questionnaire | 6 |
inflammatory bowel | 6 |
examination revealed | 6 |
severity levels | 6 |
nuclei acid | 6 |
sum test | 6 |
revealed normal | 6 |
adverse event | 6 |
isosulfan blue | 6 |
facial pain | 6 |
markov process | 6 |
potential triggers | 6 |
spss version | 6 |
higher percentage | 6 |
host response | 6 |
intubation rate | 6 |
limited data | 6 |
autoimmune hearing | 6 |
symptoms embeddings | 6 |
fexofenadine mg | 6 |
knowledge base | 6 |
jc slit | 6 |
rhinovirus infections | 6 |
rare condition | 6 |
plasma cells | 6 |
medical problems | 6 |
tablet group | 6 |
new coronavirus | 6 |
also possible | 6 |
presented severe | 6 |
negative controls | 6 |
helminth infection | 6 |
days without | 6 |
ethical standards | 6 |
cell proliferation | 6 |
allergy tests | 6 |
clinical tolerance | 6 |
may impede | 6 |
least hours | 6 |
wk ss | 6 |
mite allergic | 6 |
general practice | 6 |
immediate reaction | 6 |
tel amc | 6 |
epidemiological data | 6 |
virus shedding | 6 |
commonly associated | 6 |
kg bw | 6 |
moderate insomnia | 6 |
times per | 6 |
otolaryngologic symptoms | 6 |
randomized trial | 6 |
seven days | 6 |
emergency departments | 6 |
ics mon | 6 |
extraction methods | 6 |
six patients | 6 |
ct showed | 6 |
critically ill | 6 |
event scale | 6 |
present findings | 6 |
children suffering | 6 |
atypical patients | 6 |
transition probability | 6 |
combined immunodeficiency | 6 |
study visits | 6 |
conditionally predictively | 6 |
another study | 6 |
controlled clinical | 6 |
response relationship | 6 |
diagnosed rhinitis | 6 |
pathogenic virus | 6 |
laboratory parameters | 6 |
clinical severity | 6 |
sedimentation rate | 6 |
year follow | 6 |
using data | 6 |
act score | 6 |
upper airways | 6 |
absolute eosinophil | 6 |
cough may | 6 |
reference standard | 6 |
demographic information | 6 |
coxiella burnetii | 6 |
axis function | 6 |
groups according | 6 |
amongst healthcare | 6 |
peripheral eosinophilia | 6 |
two episodes | 6 |
patient adherence | 6 |
periostin levels | 6 |
undetectable difference | 6 |
symptom data | 6 |
among residents | 6 |
cd cell | 6 |
anxious symptomatology | 6 |
predictive values | 6 |
study investigated | 6 |
airborne transmission | 6 |
also assessed | 6 |
analyzed data | 6 |
rapid diagnosis | 6 |
per patient | 6 |
gina guidelines | 6 |
ige tests | 6 |
naepp guidelines | 6 |
nine patients | 6 |
visual user | 6 |
imaging studies | 6 |
paranasal sinuses | 6 |
mucosal inflammation | 6 |
complete questionnaire | 6 |
seven symptoms | 6 |
nasal epithelial | 6 |
slit tablet | 6 |
continuous exposure | 6 |
literature review | 6 |
skin reaction | 6 |
airway diseases | 6 |
laboratory testing | 6 |
among men | 6 |
see chart | 6 |
nasal sprays | 6 |
often referred | 6 |
olfactory dysfunction | 6 |
mean value | 6 |
ics sal | 6 |
patients taking | 6 |
authors read | 6 |
remains unclear | 6 |
ray images | 6 |
see online | 6 |
statistical power | 6 |
bilateral interstitial | 6 |
autoimmune disease | 6 |
severity classification | 6 |
penicillin allergy | 6 |
viral replication | 6 |
clinical laboratory | 6 |
cough embeddings | 6 |
allergenic extracts | 6 |
nasal irrigation | 6 |
intravenous immunoglobulin | 6 |
sociodemographic data | 6 |
experimental group | 6 |
occupational allergens | 6 |
medical students | 6 |
two consecutive | 6 |
asthma worsening | 6 |
elevated depression | 6 |
baseline characteristics | 6 |
month period | 6 |
informative ranking | 6 |
mild ad | 6 |
american college | 6 |
time period | 6 |
negatively correlated | 6 |
gi manifestations | 6 |
antiviral medications | 6 |
i rotation | 6 |
tryptase level | 6 |
allergy medication | 6 |
young age | 6 |
late summer | 6 |
graded disease | 6 |
rating depression | 6 |
sinus infection | 6 |
maintenance phase | 6 |
lay diagnosis | 6 |
occur first | 6 |
ulcer disease | 6 |
allergy skin | 6 |
atopic eczema | 6 |
healthy non | 6 |
also important | 6 |
viral hepatitis | 6 |
symptoms features | 6 |
dose ofc | 6 |
trauma type | 6 |
spinal fluid | 6 |
patient compliance | 6 |
endemic areas | 6 |
infectious agents | 6 |
bronchial epithelium | 6 |
two case | 6 |
otolaryngologic diseases | 6 |
bullet shooting | 6 |
causes common | 6 |
comparative study | 6 |
based methods | 6 |
recurrent angioedema | 6 |
like illness | 6 |
asthma morbidity | 6 |
influenza pandemic | 6 |
mold exposure | 6 |
asthma flares | 6 |
reported depression | 6 |
main analysis | 6 |
pearson correlation | 6 |
tpo ige | 6 |
sensory attribute | 6 |
ghent university | 6 |
four different | 6 |
days prior | 6 |
care patients | 6 |
antiretroviral therapy | 6 |
patients developed | 6 |
presenting symptom | 6 |
storage proteins | 6 |
getting care | 6 |
pandemic influenza | 6 |
pathogenic bacteria | 6 |
strongly agree | 6 |
year university | 6 |
salmon roe | 6 |
tumour necrosis | 6 |
case series | 6 |
cardiac involvement | 6 |
new onset | 6 |
eosinophilic asthma | 6 |
kallikrein inhibition | 6 |
cell responses | 6 |
treatment adherence | 6 |
indoor fungi | 6 |
strauss syndrome | 6 |
seven patients | 6 |
asthma may | 6 |
clinical effectiveness | 6 |
based survey | 6 |
low frequency | 6 |
nonallergic triggers | 6 |
smoking status | 6 |
case study | 6 |
outbreak soc | 6 |
san paolo | 6 |
study variables | 6 |
significant higher | 6 |
pollen seasons | 6 |
digestive tract | 6 |
symptoms also | 6 |
major depression | 6 |
information provided | 6 |
linked immunosorbent | 6 |
several years | 6 |
nonallergic rhinitis | 6 |
slit group | 6 |
local symptoms | 6 |
main symptoms | 6 |
respiratory allergy | 6 |
carrageenan patients | 6 |
usual care | 6 |
four symptoms | 6 |
recombinant protein | 6 |
mood disorders | 6 |
median time | 6 |
critical role | 6 |
clinical insomnia | 6 |
adhesion molecules | 6 |
old african | 6 |
respiratory specimens | 6 |
oxygen saturation | 6 |
index period | 6 |
ace inhibitor | 6 |
broad range | 6 |
muscle ache | 6 |
strongly associated | 6 |
epicutaneous tests | 6 |
methacholine challenge | 6 |
depression severity | 6 |
managed care | 6 |
th responses | 6 |
exposure chamber | 6 |
early morning | 6 |
lockdown among | 6 |
personal history | 6 |
still unclear | 6 |
sleep disturbance | 6 |
neuropsychiatric sequelae | 6 |
three levels | 6 |
nostril bid | 6 |
reported asthma | 6 |
onset asthma | 6 |
clinical immunology | 6 |
bronchial epithelial | 6 |
cutaneous reactions | 6 |
without aura | 6 |
following treatment | 6 |
early studies | 6 |
care utilization | 6 |
positive screen | 6 |
cd lymphocytes | 6 |
patient tolerated | 6 |
symptoms resulting | 6 |
good clinical | 6 |
pharmacologic agents | 6 |
symptoms frequency | 6 |
pmc articles | 6 |
intercellular adhesion | 6 |
rating anxiety | 6 |
mmr vaccine | 6 |
filial piety | 6 |
network differences | 6 |
hypersensitivity response | 6 |
nationwide lockdown | 6 |
people living | 6 |
health workers | 6 |
saudi arabia | 6 |
quality indicators | 6 |
detection limit | 6 |
forced vital | 6 |
health concerns | 6 |
sige levels | 6 |
care professionals | 6 |
igg binding | 6 |
ethmoid mucosa | 6 |
tongue swelling | 6 |
active metabolite | 6 |
office work | 6 |
cd ratio | 6 |
demographic variables | 6 |
lockdown accommodation | 6 |
combination therapy | 6 |
acute episodes | 6 |
highly correlated | 6 |
psychological wellbeing | 6 |
convolutional neural | 6 |
evidence suggests | 6 |
significant changes | 6 |
severe psychological | 6 |
grade fever | 6 |
hypogeusia ageusia | 6 |
inversely associated | 6 |
protein extracts | 5 |
ebola outbreak | 5 |
without atopy | 5 |
healthy smokers | 5 |
healthcare services | 5 |
clinical decision | 5 |
containing food | 5 |
severe nasal | 5 |
latin america | 5 |
complete relief | 5 |
primary antibody | 5 |
gastrointestinal disorders | 5 |
air humidification | 5 |
environmental tobacco | 5 |
total study | 5 |
network structure | 5 |
score model | 5 |
fold greater | 5 |
rapid diagnostic | 5 |
social networks | 5 |
generating procedures | 5 |
regular ocs | 5 |
throat pain | 5 |
ongoing covid | 5 |
potentially fatal | 5 |
johnson syndrome | 5 |
laboratory confirmation | 5 |
cancer treatment | 5 |
still relatively | 5 |
research group | 5 |
likely order | 5 |
human rhinovirus | 5 |
injection site | 5 |
severe rhinitis | 5 |
lumbar puncture | 5 |
multivariable analysis | 5 |
asymptomatic infection | 5 |
antihistamine treatment | 5 |
nasal airflow | 5 |
occupational status | 5 |
virus type | 5 |
mosquito bites | 5 |
cytokine levels | 5 |
idiopathic urticaria | 5 |
aspirin intolerance | 5 |
base study | 5 |
influenza dataset | 5 |
fold higher | 5 |
pay attention | 5 |
onset symptoms | 5 |
study revealed | 5 |
increased exposure | 5 |
mixed type | 5 |
legionella pneumophila | 5 |
group consisted | 5 |
significant increases | 5 |
three main | 5 |
although many | 5 |
breath sounds | 5 |
screening test | 5 |
studied using | 5 |
may become | 5 |
nearly half | 5 |
using three | 5 |
better outcomes | 5 |
sectional online | 5 |
histamine control | 5 |
cooccur method | 5 |
study provides | 5 |
drug administration | 5 |
propensity score | 5 |
exercise challenge | 5 |
joint pain | 5 |
unnecessary morbidity | 5 |
hae iii | 5 |
doxil infusion | 5 |
influenza epidemics | 5 |
developed generalized | 5 |
eosinophilic inflammation | 5 |
quinquennial media | 5 |
symptomatic patients | 5 |
food additives | 5 |
southeast asia | 5 |
found online | 5 |
south america | 5 |
left join | 5 |
respiratory muscles | 5 |
virus positive | 5 |
bronchodilator response | 5 |
barr virus | 5 |
assess whether | 5 |
additional symptoms | 5 |
symptom mentions | 5 |
sp etoh | 5 |
calculated based | 5 |
injected epinephrine | 5 |
via telephone | 5 |
interferon alpha | 5 |
positive transformation | 5 |
treatment available | 5 |
care physicians | 5 |
randomised controlled | 5 |
overall asthma | 5 |
uncontrolled asthmatics | 5 |
mycoplasma pneumonia | 5 |
perennial allergens | 5 |
autosomal dominant | 5 |
data formats | 5 |
children without | 5 |
experiencing symptoms | 5 |
piperacillin tazobactam | 5 |
i know | 5 |
least symptom | 5 |
immunosorbent assay | 5 |
specific iges | 5 |
mediated reaction | 5 |
mite exposure | 5 |
among occupants | 5 |
bronchial hyperreactivity | 5 |
since illness | 5 |
immunoglobulin replacement | 5 |
epinephrine auto | 5 |
olive tree | 5 |
fungal allergens | 5 |
higher dose | 5 |
least two | 5 |
building dampness | 5 |
less sensitive | 5 |
war veterans | 5 |
participants indicated | 5 |
outcomes among | 5 |
related variables | 5 |
medical research | 5 |
marrow biopsy | 5 |
emergency physician | 5 |
standard medical | 5 |
visible mould | 5 |
elderly population | 5 |
clinical development | 5 |
cns effects | 5 |
china joint | 5 |
available data | 5 |
pediatric visits | 5 |
american thoracic | 5 |
wilcoxon rank | 5 |
including nasal | 5 |
polyp apex | 5 |
organ involvement | 5 |
allergen avoidance | 5 |
typical respiratory | 5 |
medical attention | 5 |
pcr test | 5 |
five years | 5 |
mortality rate | 5 |
decreased risk | 5 |
may induce | 5 |
including influenza | 5 |
multivariate analysis | 5 |
febrile respiratory | 5 |
normal except | 5 |
lower prevalence | 5 |
infected people | 5 |
relevant articles | 5 |
significant positive | 5 |
improve adherence | 5 |
salsola kali | 5 |
bronchial obstruction | 5 |
screened positive | 5 |
timely mental | 5 |
successfully completed | 5 |
tissue disease | 5 |
th percentile | 5 |
rush immunotherapy | 5 |
cold urticaria | 5 |
expectorated sputum | 5 |
high anxiety | 5 |
helsinki declaration | 5 |
generally considered | 5 |
subtropical regions | 5 |
every patient | 5 |
hiv epidemic | 5 |
showed decreased | 5 |
modified version | 5 |
million pmc | 5 |
corn smut | 5 |
cell counts | 5 |
study examined | 5 |
confins cohort | 5 |
allergic individuals | 5 |
venom allergy | 5 |
good reliability | 5 |
wide variety | 5 |
strict avoidance | 5 |
vc greater | 5 |
attack rates | 5 |
may persist | 5 |
reported case | 5 |
ml respectively | 5 |
high temperature | 5 |
diary cards | 5 |
skin barrier | 5 |
inhibitor deficiency | 5 |
function testing | 5 |
showed elevated | 5 |
empty nesters | 5 |
start treatment | 5 |
discussions concerning | 5 |
studies involving | 5 |
translationally cleaved | 5 |
night cough | 5 |
serum periostin | 5 |
disease prevalence | 5 |
human rhinoviruses | 5 |
drug users | 5 |
grade iii | 5 |
total confirmed | 5 |
older children | 5 |
chinese version | 5 |
intestinal flora | 5 |
breathing difficulty | 5 |
next day | 5 |
different forms | 5 |
er visits | 5 |
physical diseases | 5 |
significant statistical | 5 |
commons attribution | 5 |
study sample | 5 |
probability sample | 5 |
negative result | 5 |
group sessions | 5 |
common causes | 5 |
will show | 5 |
readily available | 5 |
query expansion | 5 |
clinical study | 5 |
pollen concentration | 5 |
global symptom | 5 |
symptoms based | 5 |
seasonal flu | 5 |
postnasal drip | 5 |
separate study | 5 |
symptom showed | 5 |
anxiety may | 5 |
among trauma | 5 |
related mental | 5 |
primary ain | 5 |
exacerbation severity | 5 |
laryngeal edema | 5 |
middle turbinectomy | 5 |
children born | 5 |
medical specialists | 5 |
voluntary hyperventilation | 5 |
psychological problems | 5 |
starting oat | 5 |
bridge betweenness | 5 |
pip tbm | 5 |
community cases | 5 |
pericardial effusion | 5 |
consecutive patients | 5 |
pandemic among | 5 |
nerve endings | 5 |
special attention | 5 |
second year | 5 |
ann allergy | 5 |